Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Quoin Pharmaceuticals (QNRX)
NASDAQ:QNRX
RESEARCH TOOLSreports
Quoin Pharmaceuticals (QNRX) Stock Price & Analysis
247 Followers
QNRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.71 - $12.00
Previous Close$0.71
Volume34.78K
Average Volume (3M)620.03K
Market Cap
$704.78K
Enterprise Value-$2.50M
Total Cash (Recent Filing)$3.20M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)>-0.1
Beta2.27
Next Earnings
May 06, 2024EPS Estimate
-$0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.79
Shares Outstanding3,685,970
10 Day Avg. Volume71,214
30 Day Avg. Volume620,026
Standard Deviation0.26
R-Squared0.14
Alpha-0.11
Financial Highlights & Ratios
Price to Book (P/B)0.39
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.38
Forecast
1Y Price Target
$7.00Price Target Upside872.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Quoin Pharmaceuticals News
Ownership Overview
0.00%
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
QNRX FAQ
What was Quoin Pharmaceuticals’s price range in the past 12 months?
Quoin Pharmaceuticals lowest stock price was $0.70 and its highest was $12.00 in the past 12 months.
What is Quoin Pharmaceuticals’s market cap?
Currently, no data Available
When is Quoin Pharmaceuticals’s upcoming earnings report date?
Quoin Pharmaceuticals’s upcoming earnings report date is May 06, 2024 which is in 18 days.
How were Quoin Pharmaceuticals’s earnings last quarter?
Quoin Pharmaceuticals released its earnings results on Mar 13, 2024. The company reported -$2.08 earnings per share for the quarter, beating the consensus estimate of -$2.315 by $0.235.
Is Quoin Pharmaceuticals overvalued?
According to Wall Street analysts Quoin Pharmaceuticals’s price is currently Undervalued.
Does Quoin Pharmaceuticals pay dividends?
Quoin Pharmaceuticals does not currently pay dividends.
What is Quoin Pharmaceuticals’s EPS estimate?
Quoin Pharmaceuticals’s EPS estimate is -$0.76.
How many shares outstanding does Quoin Pharmaceuticals have?
Quoin Pharmaceuticals has 3,685,970 shares outstanding.
What happened to Quoin Pharmaceuticals’s price movement after its last earnings report?
Quoin Pharmaceuticals reported an EPS of -$2.08 in its last earnings report, beating expectations of -$2.315. Following the earnings report the stock price went down -13.793%.
Which hedge fund is a major shareholder of Quoin Pharmaceuticals?
Currently, no hedge funds are holding shares in QNRX
---
Quoin Pharmaceuticals Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$7.00 (872.22% Upside)
$7.00 (872.22% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.0%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.29%
12-Months-Change
Fundamentals
Return on Equity
-132.42%
Trailing 12-Months
Asset Growth
-15.83%
Trailing 12-Months
Company Description
Quoin Pharmaceuticals
Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. Cellect Biotechnology was founded by Kasbian Nuriel Chirich, Shai Yarkoni and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel.
---
QNRX Stock 12 Months Forecast
Average Price Target
$7.00
▲(872.22% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Crispr Therapeutics AG
―
Sarepta Therapeutics
―
Best Analysts Covering QNRX
1 Year
1 Year Success Rate
0/14 ratings generated profit
1 Year Average Return
-81.14%
reiterated a buy rating last month
Copying Naz Rahman's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -81.14% per trade.
---